Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00196755 | Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis | PHASE3 | COMPLETED | 138 | — | — | Dec 1, 2004 | Apr 1, 2006 | Mar 18, 2015 | 17 | Belgium, Denmark +5 |
| Arm | Type | Description |
|---|---|---|
| Sevelamer Hydrochloride (Renagel®) | EXPERIMENTAL | - |
| Calcium acetate (PhosLo® ) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Sevelamer Hydrochloride (Renagel®) | DRUG | Sevelamer hydrochloride three times per day with each meal |
| Calcium acetate (PhosLo® ) | DRUG | Calcium acetate three times per day with each meal |
Inclusion Criteria: * Willing and able to sign an informed consent form. * Men or women aged 18 years of age or older. * A diagnosis of Chronic Kidney Disease (CKD) and receiving peritoneal dialysis (Continuous cyclical peritoneal dialysis (CAPD), Automated peritoneal dialysis (APD) or Continuous c...